<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03940625</url>
  </required_header>
  <id_info>
    <org_study_id>15-002</org_study_id>
    <nct_id>NCT03940625</nct_id>
  </id_info>
  <brief_title>Anthracycline Induced Cardiotoxicity - Early Detection by Combination of Diastolic Strain and T2-mapping</brief_title>
  <acronym>ANKE</acronym>
  <official_title>Anthracycline Induced Cardiotoxicity - Early Detection by Combination of Diastolic Strain and T2-mapping</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heinrich-Heine University, Duesseldorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anthracyclines (e.g. Doxorubicin) are an important and highly effective chemotherapeutic.
      They are used in various tumor entities and are established for breast cancer treatment. The
      most significant prognostic side effect is cardiotoxicity, which occurs in up to 50 patients.
      Female gender must be considered an independent risk factor for the incidence and severity of
      associated heart failure. The aim of this study is to demonstrate that dose-dependent
      anthracycline-induced cardiotoxicity has a measurable effect on T2 mapping on MRI. The second
      aim is to demonstrate if the combination of diastolic strain (echo and MRI) and T2 mapping
      can detect earlier anthracycline-induced myocardial damage than via the established method of
      the echocardiographic measurement of LV-EF and the conventional quantification of diastolic
      function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In order to answer the question, patients with breast cancer, who will undergo a
      chemotherapeutic treatment with antracycline, will be examined before chemotherapy (including
      cmr and echocardiography) and after chemotherapy at different times within one year.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 3, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>reduction of the left ventricular ejection fraction (LV-EF) by 10% to under 50%</measure>
    <time_frame>after 12 months</time_frame>
    <description>volumetric determination of LV-EF</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>reduction of the left ventricular global longitudinal strain (GLS) by over 15%</measure>
    <time_frame>after 12 months</time_frame>
    <description>determination of GLS via strain analysis</description>
  </secondary_outcome>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Myocardial Damage</condition>
  <condition>Cardiotoxicity</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiac MRI and echocardiography, laboratory parameters</intervention_name>
    <description>Cardiac MRI including cine imaging (volumetric determination of LV-EF), late gadolinium enhancement, strain analysis, T1 mapping and T2 mapping Echocardiography including 3D-EF, diastolic function and strain analysis Determination of laboratory parameters including cardiac enzymes (Troponin T and high sensitivity Troponin T) and cardiac markers (BNP and NT-pro BNP)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Planned therapy with an anthracycline and at least 1 year follow up

          -  &gt;18 years of age

          -  written informed consent

        Exclusion Criteria:

          -  prior cardiovascular disease

          -  diabetes mellitus

          -  previous therapy with anthracyclines
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Florian Bönner, MD</last_name>
    <email>ctsu@med.uni-duesseldorf.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Cardiology, Pulmonary Disease and Vascular Medicine</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Bönner, MD</last_name>
    </contact>
    <investigator>
      <last_name>Florian Bönner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick Behm, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 6, 2019</study_first_submitted>
  <study_first_submitted_qc>May 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2019</study_first_posted>
  <last_update_submitted>August 6, 2019</last_update_submitted>
  <last_update_submitted_qc>August 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heinrich-Heine University, Duesseldorf</investigator_affiliation>
    <investigator_full_name>Klinik für Kardiologie, Pneumologie und Angiologie</investigator_full_name>
    <investigator_title>PD Dr. Florian Bönner</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>antracyclines</keyword>
  <keyword>cardiotoxity</keyword>
  <keyword>myocardial damage</keyword>
  <keyword>MRI</keyword>
  <keyword>T2 mapping</keyword>
  <keyword>diastolic function</keyword>
  <keyword>echocardiography</keyword>
  <keyword>early detection</keyword>
  <keyword>strain analysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

